Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma
Plain-language summary
This trial is testing a hypomethylating agent (azacitidine or decitabine) based regimen for patients with angioimmunoblastic T-cell lymphoma (AITL) or TFH lymphomas, anaplastic large cell lymphoma (ALCL), cutaneous T-cell lymphoma (CTCL), enteropathy-associated T-cell lymphoma, hepatosplenic T-cell lymphoma, monomorphic epitheliotropic intestinal T-cell lymphoma, peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), or subcutaneous panniculitis-like T-cell lymphoma whose disease has come back or stopped responding to prior treatment. This is a Phase 1 trial, which means researchers are finding the right dose and this is among the earliest testing in patients. Patients are randomly assigned to different treatment groups. This trial is available at 1 location in the United States. The trial is not yet open for recruitment.
Who can join (key eligibility)
- Age 18 Years or older
- Lymphoma came back or did not respond to prior treatment
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Azacitidine (DRUG): Given SC | Belinostat (DRUG): Given IV | Biospecimen Collection (PROCEDURE): Undergo blood sample collection | Computed Tomography (PROCEDURE): Undergo CT or PET/CT | FDG-Positron Emission Tomography (PROCEDURE): Undergo FDG-PET | Fludeoxyglucose F-18 (OTHER): Given FDG | Positron Emission Tomography (PROCEDURE): Undergo PET/CT | Pralatrexate (DRUG): Given SC | Questionnaire Administration (OTHER): Ancillary studies
Azacitidine, Belinostat, Biospecimen Collection, Computed Tomography, FDG-Positron Emission Tomography, Fludeoxyglucose F-18, Positron Emission Tomography, Pralatrexate, Questionnaire Administration
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details